Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kai Uwe Chow

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Current Medical Research and Opinion|December 21, 2011
Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originatorJürgen Stein, Axel Dignass, Kai Uwe Chow
Radiology|October 29, 2015
Spleen Size Is Significantly Influenced by Body Height and Sex: Establishment of Normal Values for Spleen Size at US with a Cohort of 1200 Healthy IndividualsKai Uwe Chow, Beate Luxembourg, Erhard Seifried, et al.
Anti-Cancer Drugs|June 4, 2011
Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanismSimone Boehrer, Petra Schroeder, Tina Mueller, et al.
Current Pharmaceutical Design|February 4, 2006
Novel agents aiming at specific molecular targets increase chemosensitivity and overcome chemoresistance in hematopoietic malignanciesSimone Boehrer, Daniel Nowak, Dieter Hoelzer, et al.
Current Medicinal Chemistry|August 22, 2006
The molecular biology of TRAIL-mediated signaling and its potential therapeutic exploitation in hematopoietic malignanciesSimone Boehrer, Daniel Nowak, Dieter Hoelzer, et al.
Biochemical Pharmacology|September 2, 2003
Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activationKai Uwe Chow, Daniel Nowak, Simone Boehrer, et al.
Cancer Immunology, Immunotherapy : CII|August 25, 2007
Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cellsTina Müller, Christoph Uherek, Guitta Maki, et al.
European Journal of Haematology|July 14, 2011
Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemiaKai Uwe Chow, Soo-Zin Kim, Nils von Neuhoff, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|December 1, 2004
In malignant myeloid cells expression of Daxx downregulates expression of p53 and of the inhibitors of apoptosis proteinsSimone Boehrer, Daniel Nowak, Simone Schaaf, et al.
Leukemia & Lymphoma|December 29, 2004
Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART)Timo Wolf, Hans-Reinhard Brodt, Stephan Fichtlscherer, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Current Medical Research and Opinion|December 21, 2011
Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originatorJürgen Stein, Axel Dignass, Kai Uwe Chow
Radiology|October 29, 2015
Spleen Size Is Significantly Influenced by Body Height and Sex: Establishment of Normal Values for Spleen Size at US with a Cohort of 1200 Healthy IndividualsKai Uwe Chow, Beate Luxembourg, Erhard Seifried, et al.
Anti-Cancer Drugs|June 4, 2011
Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanismSimone Boehrer, Petra Schroeder, Tina Mueller, et al.
Current Pharmaceutical Design|February 4, 2006
Novel agents aiming at specific molecular targets increase chemosensitivity and overcome chemoresistance in hematopoietic malignanciesSimone Boehrer, Daniel Nowak, Dieter Hoelzer, et al.
Current Medicinal Chemistry|August 22, 2006
The molecular biology of TRAIL-mediated signaling and its potential therapeutic exploitation in hematopoietic malignanciesSimone Boehrer, Daniel Nowak, Dieter Hoelzer, et al.
Biochemical Pharmacology|September 2, 2003
Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activationKai Uwe Chow, Daniel Nowak, Simone Boehrer, et al.
Cancer Immunology, Immunotherapy : CII|August 25, 2007
Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cellsTina Müller, Christoph Uherek, Guitta Maki, et al.
European Journal of Haematology|July 14, 2011
Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemiaKai Uwe Chow, Soo-Zin Kim, Nils von Neuhoff, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|December 1, 2004
In malignant myeloid cells expression of Daxx downregulates expression of p53 and of the inhibitors of apoptosis proteinsSimone Boehrer, Daniel Nowak, Simone Schaaf, et al.
Leukemia & Lymphoma|December 29, 2004
Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART)Timo Wolf, Hans-Reinhard Brodt, Stephan Fichtlscherer, et al.
Pageof 3